[The use of the vasoconstrictor hemostatic Remestyp in surgical obstetrics].
Terlipressin (Remestyp) or N-a-triglycyl-(8-lysme) vasopressin after parenteral application and slow enzymatic cleavage releases synthetic analog of vasopressin-8-lysine-vasopressin. It is potent myometrial stimulator in pregnant and non-pregnant uterus and at the same time decreases myometrial and endometrial blood flow. Remestyp has synergistic effect with oxytocin and/or methergin. Our experience shows good effect of Remestyp in the complex treatment of cases with hypotonic uterus, placenta praevia or adherence during and after abdominal or vaginal birth. Injection of Remestyp around the fibroids during cesarean section significantly decrease the blood lost and make the myomectomy safer. We observe decrease of oozing at the incision of the skin and stopping initial subfascial hematoma.
Dimitrov
A
A
D005260:Female; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008236:Lypressin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013513:Obstetric Surgical Procedures; D010923:Placenta Previa / Q000188:drug therapy; D011182:Postoperative Care; D019106:Postoperative Hemorrhage / Q000188:drug therapy; D011247:Pregnancy; D000077585:Terlipressin; D014592:Uterine Hemorrhage / Q000188:drug therapy; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
D006490:Hemostatics; D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin